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Summary
Introduction: Agonist Opioid Treatments (AOT) have been, in comparison to healthy controls, associated with neuro-
cognitive impairment in different domains. This review identifies differences in neurocognitive function as a result of 
treatment with either buprenorphine or methadone. Method: A qualitative and systematic literature review of published 
articles from 1946 to 29/2/2016 on neurocognitive function of patients prescribed buprenorphine or methadone and com-
pared with healthy patients utilising the Meta-analysis of Observational Studies in Epidemiology (MOOSE) guidelines. 
Results: The limited data demonstrate buprenorphine as presenting with fewer neurocognitive impairments, in cognitive 
impulsivity, cognitive flexibility and attention domains when compared with methadone. However both treatments mo-
dalities presented with more impairments in neurocognitive function domains, including short term memory, attention, 
cognitive flexibility, cognitive impulsivity, motor impulsivity and non planning impulsivity, when compared with healthy 
control groups. Discussion: The lack of published papers in comparing neurocognitive impairment between the treatment 
modalities limit interpretation of this systematic review. Conclusion: Further methodologically rigid and higher quality 
research into the neurocognitive effects of these treatment modalities in the opioid dependent populations, especially 
when in treatment, is urgently required.
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11. Introduction
Treatment for opioid (and opiate) addiction us-
ing agonist opioid treatments (AOT) (i.e. methadone 
and buprenorphine) have been associated with neuro-
cognitive impairment in comparison to healthy con-
trols.
For the purposes of this review we will use the 
term opioids to encompass both opiates and opioids. 
Opioids are widely used both legally in treatment, for 
their analgesic effects, and illicitly, for the psycho-
tropic effects. The neurocognitive impairments asso-
ciated with opioid use have already been documented 
[4]
Opioids are known to alter receptor sensitivity 
and expression, demonstrating a tolerance effect, but 
also display psychological dependence by altering the 
brains behavioural circuits. The receptors affected by 
opioids, are located through the brain and spinal cord, 
including the thalamus, hypothalamus, hippocampus, 
amygdala and the cerebral cortex [12],which are im-
portant for neurocognitive function, but are also con-
nected to the reward and reinforcement area in the 
brain, the nucleus accumbens.
Opioid use has been demonstrated in the brain to 
increase oxidative stress, which contributes to neuro-
toxicity leading to neurocognitive impairment [7, 33].
In the review by Büttner and Mall, they noted re-
duced neuronal density in majority of patients dying 
from heroin overdoses due to respiratory depression 
and associated brain hypoxia [6].
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than the direct opioid toxic effects on neurocognitive 
impairment needs to be considered. This can include 
bacterial and viral infection and other potential neu-
ropathological insults [10]. These factors will not be 
reviewed in this systematic review.
To measure neurocognitive function in individu-
als the precise function being tested must be defined. 
Muriel Lezak, the author of the first book exploring 
neuropsychological assessment, wrote ‘Direct obser-
vation of the fully integrated functioning of living hu-
man brains will probably always be impossible’ [18]. 
Therefore, to assess neuropsychological function in 
the context of assessment, three domains (and sub-
sequent sub-domains based on neurocognitive tests) 
need to be clearly defined to allow the objective ob-
servation of neurocognitive function in individuals:
• Intelligence
• Executive Function
• Memory and Learning
The use of an intelligence assessment allows an 
estimate the premorbid IQ of an individual. A vocab-
ulary test is the primary assessment method use, e.g 
Shipley Institute of Living Scale (SILS) or Wechsler 
Adult Intelligence Scale – Revised & III [31, 38]. 
High level neurocognitive functions, known as 
Executive functions, allow for the control of behav-
iour to achieve a targeted outcome, this includes cog-
nitive flexibility, cognitive planning, cognitive impul-
sivity, working memory and attention [5, 11, 36].
Memory and learning assesses an individual’s 
ability to recall and make new memories. The Atkin-
son-Shiffrin model of memory proposes three distinct 
‘stores’ of memory: sensory memory (lasting a few 
milliseconds: providing a buffer for sensory informa-
tion and allows us to address information when re-
quired), short-term memory (lasting 12-30 seconds 
without rehearsal: primarily auditory in nature, can 
store around seven chunks of information for a few 
seconds without rehearsal [22] duration of storage 
can be increased with the use of a phonological loop), 
and long term memory which can be indefinite (abil-
ity to store information for a lifetime [2] and can be 
further split into declarative memory requiring con-
scious though and procedural memory requiring no 
thought). 
A recent meta analysis looking at the effects of 
chronic methadone use identified global impairments 
in neurocognitive function relative to healthy partici-
pants [5]. 
This article aims to determine if there are dif-
ferences in the effects on the neurocognitive function 




A literature review identified articles relating 
to the neurocognitive effects of either buprenorphine 
Table 1: Inclusion and exclusion criteria for studies used in the review
Inclusion Exclusion
Participants aged eighteen or over with chronic opioid de-
pendence and currently engaged in an opioid maintenance 
programme
Cohorts with current uncontrolled poly-drug use (nicotine 
excluding).
Individuals needed to be compared to either healthy 
controls, abstinent individuals or another maintenance pro-
gramme (methadone vs. buprenorphine) through the use of 
validated neuropsychological assessments.
Cohorts with a diagnosis of any Axis-1 psychiatric ill-
ness (excluding substance related disorders) as defined 
by DSM-IV/V (American Psychiatric Association 2000; 
American Psychiatric Association 2013).
Neuropsychological assessments needed to be identi-
fied and validated to allow for them to be classified into 
domains. If novel assessments were used a description of 
the cognitive functions assessed was used to classify by 
comparison to a defined assessment.
Cohorts with previous serious head injury.
Identified papers need to be of adequate quality match-
ing the control/abstinent group to the maintained cohort, 
matching criteria should include: age, sex, years of educa-
tion and years of heroin dependence
Articles with poor quality methodology,
Papers needed to report separate results for each cohort 
and test, papers which combined maintenance cohorts 
were excluded as it was not possible to extract the results 
required.
Cohorts including participants who were HIV serotype 
positive
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or methadone on patients receiving Agonist Opioid 
Treatment (AOT) for opioid dependence. The cohorts 
chosen where either direct comparison between indi-
viduals treated with methadone or buprenorphine or 
those compared against a healthy control group. The 
Meta-analysis of Observational Studies in Epidemi-
ology (MOOSE) guidelines were employed and the 
inclusion and exclusion criteria used have been tabu-
lated in Table 1.
An electronic based search using a number of 
databases and incorporating articles published from 
1946 to 29/2/2016 were used. The databases used 
where Ovid MEDLINE (1946 to 29/2/2016); EM-
BASE (1974 to 29/2/2016); PUBMED (1964 to 
29/2/2016); PsychINFO (1980 to 29/2/ 2016). There 
were no language constraints employed.
The articles were identified using the search 
headings in Table 2.
The search terms ‘neuropsychological tests’ and 
‘neurocognitive tests’ were then replaced with the 
sub-titles of neurocognitive domains e.g. Short Term 
Memory, Long Term Memory, Attention, Cognitive 
Flexibility, Cognitive Impulsivity, Motor Impulsivity 
and Non-Planning Impulsivity.
As this article is a literature review there was 
no requirement for ethical approval in relation to the 
study.
13. Results
13.1. Data analysis and study detail
The literature search provided very few articles 
published on the comparison of effects of treatment 
on the neurocognitive function of patients being treat-
ed with buprenorphine or methadone. 
With the very limited number of published arti-
cles offering direct comparisons (3 articles identified) 
between buprenorphine and methadone, a wider but 
indirect comparison of the effects on neurocognitive 
function were used from articles comparing either of 
the two therapeutic intervention against a healthy pa-
tient control group. The results of these studies were 
used to comment on the potential for neurocognitive 
impairment from the treatment with ORT against a 
control group.
13.2. Assessment of study quality
The vast majority of selected articles for this re-
view were assessed as fair in quality using the NIH 
Quality Framework for case-control studies (Table 3) 
(NIH 2014) with others ranging in quality from poor 
(2 articles) to good (1 article). All studies were obser-
vational case control studies.
13.3. Number of articles identified
The initial literature search identified 426 ar-
ticles from literature and other sources. Once du-
plicates were removed the total number of relevant 
manuscripts was reduced to 179. Titles and abstracts 
of 31 articles included in the accepted abstracts were 
screened for eligibility with an additional six articles 
included in the full text screening (Figure 1: QUO-
RUM). The full text of the remaining 36 articles was 
assessed using the inclusion and exclusion criteria on 
Table 1. This assessment excluded a further 20 arti-
cles which failed to meet the inclusion criteria in the 
full text with the remaining 16 articles included in 
this review. 
13.4. Cohorts identified
The included articles described results from the 
direct comparison of 60 buprenorphine maintained 
individuals to 74 methadone maintained individu-
als from 3 published articles. When the search was 
extended to compare either methadone or buprenor-
phine maintained patients to a healthy control, there 
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were the neurocognitive assessments of 279 metha-
done maintained individuals from 10 published arti-
cles and 84 individuals maintained on buprenorphine 
compared to healthy controls from 5 published papers 
[34], although one article is included in each com-
parison in the table as it compared healthy controls 
against methadone and buprenorphine and in ad-
dition a direct comparison between methadone and 
buprenorphine groups.
The papers included are shown in table 6. 
13.5. Neurocognitive impairments between groups
In the articles directly comparing patients on 
ORT treatment [1, 25, 34], all except one domain 
(cognitive impulsivity) showed no significant differ-
ences between cognitive functioning in methadone 
and buprenorphine treated individuals.
13.5.1. Cognitive impulsivity
Buprenorphine maintained individuals scored 
significantly better (p<0.05) on measures of cognitive 
impulsivity than methadone maintained individuals 
in all three selected studies [1, 25, 34]. This is also 
supported by all other selected studies measuring this 
Buprenorphine Vs. 
Methadone 
n = 3 
Buprenorphine Vs. 
Abstinence 
n = 1 
Buprenorphine Vs. 
Healthy Control 
n = 5 
Methadone Vs. 
Abstinence 
n = 4 
Methadone Vs. 
Healthy Control 





through other sources. 
(n=218) 
Abstracts screened after duplicates removed. 
(n=179) 
Full-text Articles Assessed for Eligibility 
(n=37) 
Articles included in the Final Review 
N= 16
N = 17
Records Excluded (n=142) 
Poly Drug Use (n=23) 
No Control (n=25) 
Participants Under 18 (n=14) 
Current Heroin Users (n=3) 
HIV Positive (n=17) 
Axis-1 Illness (n=4) 
No Neuropsychological Tests (n=23) 
No Maintenance Therapy (n=21)  
No English Article Available (n=2) 
Animal Study (n=1)  
Acute Effects of Opioids (n=9) 
Articles Excluded (n=20) 
Poly Drug Use (n=7)  
Head Injury (n=3) 
Mixed Results Group (n=3)  
No  Control  (n=2)  
Acute Effects (n=2) 
Control Group Seeking Psychological 
Treatment for Pain (n=1) 
No English Article Available (n=1)  
Only Abstract Available (n=1) 
Figure 1. QUORUM
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nificantly impaired (p<0.05) relative to healthy con-
trols in both methadone and buprenorphine cohorts. 
Four of the identified studies found a significant im-
pairment (p<0.05) when methadone maintained indi-
viduals were compared to healthy controls [3, 8, 25, 
27]. Three of the studies comparing buprenorphine 
to healthy controls showed significant impairment 
(p<0.05) in short term memory [21, 25, 34]. 
14. Discussion
14.1. Summary of findings
Buprenorphine maintained individuals demon-
strate reduced impairment of cognitive impulsivity 
compared to those maintained on methadone. This 
was the most reliable conclusion drawn from the re-
sults as a significant difference was observed both in 
papers directly comparing methadone with buprenor-
phine and comparisons with control groups. 
The attention domain shows that buprenorphine 
patients are less impaired than patients on metha-
done in the direct comparative studies. However, in 
the articles comparing methadone or buprenorphine 
to healthy controls, both treatments were shown to 
cause equal impairment. The differences between 
buprenorphine and methadone in relation to the at-
tention domain could be due to the increased sedation 
experienced with a full opioid agonist in comparison 
to a partial agonist [29].
Cognitive flexibility was reported to be sig-
nificantly less impaired (p<0.05) in buprenorphine 
maintained cohorts than methadone when compared 
to healthy controls. However this was not replicated 
in articles that directly compare the domain between 
methadone or buprenorphine maintained patients.
14.2. Significance
As the literature search demonstrated, using the 
strict criteria employed in this review, there is little 
evidence available currently to directly compare both 
buprenorphine and methadone maintenance therapies 
in relation to neurocognitive function. The articles 
that have been included highlights that there are dif-
ferences between treatments and these may provide 
benefits for patients increasing the success of their 
treatment. However there is a lack of consistency in 
the tests employed in the research to date. 
14.3. Strength and Limitations
cognitive domain and compared with healthy con-
trols [3, 23, 25, 28, 30, 34]. There was however no 
significant difference found in cognitive impulsivity 
between buprenorphine maintained individuals and 
healthy controls [25, 30, 34].
13.5.2. Cognitive flexibility
In the three studies directly comparing metha-
done to buprenorphine treatment there were no sig-
nificant differences in cognitive flexibility scores 
reported. However cognitive flexibility was more fre-
quently reported as significantly impaired (p<0.05) in 
patients maintained on methadone, than those on bu-
prenorphine when compared to healthy controls. Four 
of the ten selected studies [8, 23, 25, 34], showed im-
pairment for methadone maintained individuals com-
pared to healthy control. In comparison only one of 
five studies that reviewed cognitive flexibility in bu-
prenorphine treated individuals identified impairment 
[34],with the other 4 papers finding no impairment in 
this domain in comparison to healthy controls.
13.5.3. Motor impulsivity 
In the three papers conducting the direct com-
parison between methadone treatment and buprenor-
phine treatment, there were no reported differences in 
the motor impulsivity. However in the studies looking 
at comparison to healthy controls, both methadone 
and buprenorphine treated cohorts exhibited impair-
ments in motor impulsivity when compared to healthy 
controls [32, 34]. 
13.5.4. Attention
One measure (DR2) in relation to the attention 
domain found buprenorphine individuals were less 
impaired than methadone in the papers comparing 
treatments against each other directly [1]. However 
the same paper found no significant difference on two 
other assessments of attention (Q1 & FAT). Soyka 
[34] also found no significant difference in attention 
test scores when comparing methadone to buprenor-
phine. Five articles that compared methadone to 
healthy controls identified a significant impairment in 
attention [8, 19, 23, 30, 34] with four buprenorphine 
comparison papers showed an impairment (p<0.05) 
in the attention domain [30, 21, 32, 34].
13.5.5. Short term memory
 From the two direct comparison articles between 
methadone and buprenorphine cohorts that reported 
on Short Term Memory, there was no significant dif-
ference found [25, 34]. Short term memory was sig-
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tems. A large degree of heterogeneity existed between 
studies, e.g. mean opioid use ranged from six months 
to over fifteen years between methadone cohorts [25, 
28]. Other demographics followed similar trends, e.g. 
mean buprenorphine dose ranged from 6.78mg [21] 
to 13.4mg [1]. There were significant differences re-
ported between comparable populations within indi-
vidual selected studies. There were discrepancies in 
age, gender and educational attainment between pop-
ulations [3, 20, 25, 27]. Significant differences in the 
completed educational years could have a profound 
effect on the neurocognitive test scores reported by 
these groups in the intelligence domain. Matching 
controls based on an estimate of their pre-morbid in-
telligence (IQ) will reduce this bias.
The time between administration of the mainte-
nance dose and conducting the neurocognitive assess-
ments needs to be considered as variations in the time 
delay may have different impairments on neurocogni-
tive function due to the acute sedative effects of the 
treatment modality used [5]. One paper analysed the 
difference in scores between peak levels (1.5 hours 
after administration) and trough levels (20 hours after 
administration) for both methadone and buprenor-
phine. The combined results showed that individuals 
at trough levels performed significantly worse on the 
RST3 assessment of motor impulsivity [1]. In this re-
view, the majority of studies included did not specify 
the time between administration of the last dose and 
neuropsychological test which impacts on repeat-
ability and result interpretation. The large variation 
in duration of action means that individuals main-
tained on different opioids may experience the onset 
of withdrawal symptoms, at different times which 
may affect the neurocognitive assessment. Thus, if 
the assessment is conducted at the same time post ad-
ministration; the methadone maintained cohort may 
collectively experience withdrawal symptoms earlier 
than the buprenorphine maintained cohort in direct 
comparison studies. Some studies screened for opioid 
withdrawal at the time of testing ensuring participants 
were not in withdrawal [30, 37], whilst others con-
ducted assessments well within the duration of action 
of treatments [3, 17]. 
Multiple different cognitive domains are de-
scribed and used in the literature. For the purposes of 
this enquiry the domains set out by Baldacchino et al. 
[4] were used.
Until a standardised system of domains and as-
sessment exists there will always be discrepancies 
and variations in the tests used and subsequent result 
classification, damaging the integrity of conclusions 
The literature search found no Randomised 
Control Trials (RCTs) and all articles included are 
case-control studies. The lack of randomized blinded 
studies limits result reliability due to the possibility of 
increased bias [15]. Due to methodological difficul-
ties, patients were not blinded to their interventional 
group with only two articles used a single blinded 
methodology [1, 30].
Articles were excluded if they included indi-
viduals affected by simultaneous illicit drug use or 
medication that might affecting neurocognitive func-
tion to minimise the effect of compounding factors. 
Most articles used different definitions of simulta-
neous drug use, showing a differing application of 
exclusion criteria between papers. Some conducted 
urinalysis over a period of months and others allowed 
for positive urine test if the individual was not expe-
riencing acute effects. The most commonly identified 
additional substance was benzodiazepines, which are 
known to have effects on neurocognitive function [8, 
28, 34, 37]. These mitigate the acute effects of ben-
zodiazepines on the result of the neurocognitive tests 
and question the cause of any reported neurocogni-
tive impairments in these studies. This becomes more 
important when comparing buprenorphine due to the 
limited number of papers available covering this area. 
The less robust exclusion criteria used in Soyka’s [34]
paper reduces the reliability of the results from this 
study. The results mirror those from the other three 
papers making this comparison [1, 25, 30], reducing 
the likelihood that benzodiazepine use caused these 
results. However it must be noted that benzodiazepine 
use is frequent amongst active heroin users, as well as 
those enrolled in maintenance opioid agonist replace-
ment programmes. [16]. None of the studies consid-
ered the potential neurocognitive sequelae of chronic 
nicotine and/or cannabis use in this treatment seeking 
population.
The selected articles sample size lack consist-
ency across the five studies investigating buprenor-
phine. They included 84 individuals, contrasting to 
279 methadone maintained individuals across 10 
selected studies. Potential root causes of this differ-
ence in articles identified are; (a) the limited period 
of time that buprenorphine preparations have been 
licensed for use in opioid dependence (mid-1990s 
for buprenorphine as opposed to methadone’s avail-
ability since the 1960s) and (b) methadone being the 
preferential use of methadone as a first line treatment 
to opioid dependence [39]. 
The published articles are using small numbers 
studying individuals attending diverse treatment sys-
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heavy machinery. However for some patients a degree 
of cognitive impairment may be beneficial. E.g. states 
of increased boredom and “problematic thoughts that 
can increase the risk of relapse” [35]. This observation 
should be taken with extreme caution as this system-
atic review has highlighted the urgent need to conduct 
methodologically sound, unbiased and well powered 
studies to be able to identify better significant corre-
lation between observed neurocognitive impairments 
and type of agonist opioid treatment used with clini-
cal practice.
15. Conclusions
In conclusion, this systematic review of pub-
lished literature into the neurocognitive function of 
individuals on methadone or buprenorphine mainte-
nance treatment shows that there are fewer than ex-
pected reports of impaired neurocognitive function 
when patients are prescribed buprenorphine in com-
parison to methadone. There is a need for more rigor-
ous and larger well matched longitudinal studies to 
reduce the variances caused due to opioid withdrawal 
influencing the result and to measure neurocognitive 
impairment of pharmacologically maintained indi-
viduals over time. 
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